Prosecution Insights
Last updated: October 21, 2026
Application No. 18/246,773

MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF

Final Rejection §112
Filed
Sep 27, 2023
Priority
Sep 28, 2020 — RE 10-2020-0126423 +1 more
Examiner
STOCKTON, LAURA LYNNE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Huons Co. Ltd.
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1028 granted / 1366 resolved
+15.3% vs TC avg
Strong +34% interview lift
Without
With
+33.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
46 currently pending
Career history
1396
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
22.7%
-17.3% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
35.6%
-4.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1366 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 7-20, 22 and 25-27 are pending in the instant application. Election/Restrictions Applicant’s election without traverse of Group III (now Revised Group I as shown below), Group I, claims 1-5 and 7-22, drawn to products of Chemical Formula 1 and Chemical Formula 2, PNG media_image1.png 170 226 media_image1.png Greyscale PNG media_image2.png 170 358 media_image2.png Greyscale and the species of Compound TDH-358, disclosed in paragraph [00442] on pages 108-109 of the instant specification (reproduced below), PNG media_image3.png 196 574 media_image3.png Greyscale , in the reply filed on April 21, 2026 was acknowledged in the previous Office Action. The requirement was deemed proper and therefore made FINAL in the previous Office Action. Claims 6 and 23-27 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on April 21, 2026. Claims 6, 23 and 24 have been cancelled per the Amendment filed August 13, 2026. Drawings The drawing was received on August 13, 2026. The drawing is acceptable. Rejections and objections made in the previous Office Action that do not appear below have been overcome by Applicant’s amendments to the claims. Therefore, arguments pertaining to these rejections and objections will not be addressed. As a result of the current amendments to the claims per the amendment filed August 13, 2026, the following rejections and objection apply. Claim Objections Claims 7, 18 and 20 are objected to because of the following informalities: in currently amended claim 7, under the definition of variable R2, the phrase “and each independently hydrogen” should have been “and are each independently hydrogen” (line 1 of page 4); in currently amended claim 18, under the definition of variables A2 and A3, an “or” should have been added after “phenyl,” for proper Markush language format; and in currently amended claim 20, the period added at the end of Compound TDH-555 should have been added at the end of the claim (i.e., outside of the bottom of the table). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8, 12 and 14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Currently amended claim 8 is confusing because the R2 variable in claim 8 does not represent “alkoxy” but then claim 8 states “wherein the alkyl, alkoxy, … is unsubstituted or substituted”. Therefore, currently amended claim 8 is indefinite. Originally filed claim 12 now lacks antecedent basis from currently amended claim 11. Claim 11 is currently amended whereby the definition of variable A3 was amended by deleting the following three rings from its definition, PNG media_image4.png 88 246 media_image4.png Greyscale and PNG media_image5.png 62 102 media_image5.png Greyscale , and the definitions of the variables which are a part of these three rings were also deleted. However, a multitude of linkers listed in claim 12 are now affected by the deletion of these three rings from claim 11 so that claim 12 now lacks antecedent basis from claim 11. See, for example, the linker in column 1, row 1 on page 8 in claim 12; the linker in column 1, row 3 on page 8 in claim 12; both linkers on rows 4-6 on page 8 in claim 12; etc. Therefore, claim 12 is now indefinite. Currently amended Claim 14 lacks antecedent basis from claims 7 and 13 because there is no earlier recitation in currently amended claim 7 for the definition of variable X as found in claim 14 (see the last line of page 9). Independent claim 7 defines variable X as representing N or CH but claim 14 defines variable X as representing C(O) or C(R3)2. Therefore, currently amended claim 14 is indefinite. Currently amended claim 14 lacks antecedent basis from claims 7 and 13 because there is no earlier recitation in claim 7 for the definition of variable R1 as found in claim 14. Independent claim 7 defines variable R1 as representing –(CH2)n-, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or -A-(B)-. However, claim 14 defines variable R1 as representing hydrogen, nitro, NH2, etc. (lines 2-3 of page 10). Therefore, currently amended claim 14 is indefinite. Currently amended claim 14 lacks antecedent basis from claims 7 and 13 because there is no earlier recitation in currently amended claim 7 for the definition of variable R3 as found in claim 14. Independent claim 7 defines variable R3 as representing C1-10alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl. However, claim 14 defines variable R3 as representing hydrogen or C1-C3 alkyl (lines 4-5 of page 10). Therefore, currently amended claim 14 is indefinite. Currently amended claim 14 lacks antecedent basis from claims 7 and 13 because there is no earlier recitation in claims 7 and 13 for the definitions of variables A and B as found in claim 14. See lines 13-15 of claim 7 for the definitions of variables A and B and the last two lines of page 11 for the definition of variable A in claim 14 and the last line of claim 14 for the definition of variable B. Therefore, currently amended claim 14 is indefinite. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 12 and 14 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 12 now fails to further limit currently amended claim 11 because claim 12 is now broader in scope than claim 11. Currently amended claim 11 does not indicate that the linker moieties can represent a number of linkers listed in claim 12 such as the linker PNG media_image6.png 70 144 media_image6.png Greyscale (column 1, row 1 on page 8), the linker PNG media_image7.png 88 144 media_image7.png Greyscale (column 1, row 3 on page 8) due to the amendment to the definition of variable A3 in claim 11. Claim 14 fails to further limit the claims from which it depends because claim 14 is broader in scope than the claims from which it depends for several reasons. Firstly, the definition of variable X as found in claim 14 is not stated in claims 7 or 13. Secondly, the definition of variable R1 as found in claim 14 is not stated in claims 7 or 13. Thirdly, the definition of variable R3 as found in claim 14 is not stated in claims 7 or 13. Fourthly, the definitions of variables A and B as found in claim 14 are not stated in claims 7 or 13. Allowable Subject Matter The elected species of Compound TDH-358, disclosed in paragraph [00442] on pages 108-109 of the instant specification, is free of the prior art of record. Claims 9-11, 13, 15-20 and 22 are objected to as being dependent upon either a rejected or an objected to base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. This application contains claims 25-27 drawn to an invention nonelected without traverse in the reply filed on April 21, 2026. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP §821.01. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to: Laura L. Stockton (571) 272-0710. The examiner can normally be reached on Monday-Friday from 8:30 am to 6 pm, Eastern Standard Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s acting supervisor, James Alstrum-Acevedo can be reached on 571/272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAURA L STOCKTON/ Primary Examiner, Art Unit 1626 Work Group 1620 Technology Center 1600 October 5, 2026 Book XXIX, page 61
Read full office action

Prosecution Timeline

Sep 27, 2023
Application Filed
Jun 16, 2026
Non-Final Rejection mailed — §112
Aug 13, 2026
Response Filed
Oct 07, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767656
TRICYCLIC COMPOUND AND USE THEREOF
3y 3m to grant Granted Oct 20, 2026
Patent 12747251
INHIBITOR OF BTK AND MUTANTS THEREOF
4y 6m to grant Granted Sep 29, 2026
Patent 12741960
PIKFYVE KINASE INHIBITORS
4y 1m to grant Granted Sep 22, 2026
Patent 12723031
Preparation Process of 1-N-Methyl-2-Nitro-5-Hydroxymethyl Imidazole
3y 2m to grant Granted Sep 01, 2026
Patent 12698299
BIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING SUCH LIGANDS, AND CATALYTIC PROCESSES UTILIZING SUCH CATALYTIC COMPOSITIONS
1y 6m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
99%
With Interview (+33.7%)
2y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1366 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month